In Silico Hypothesis Testing in Drug Discovery: Using Quantitative Systems Pharmacology Modeling to Evaluate the Therapeutic Value of Proinsulin Conversion to Insulin Therapy for Type 2 Diabetes Mellitus
Open Access
- 26 November 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (12) , 1522
Abstract
Background/Objectives: Proinsulin, the precursor to insulin, has limited activity on the insulin receptor. Proinsulin levels increase with increasing insulin resistance in type 2 diabetes due to incomplete processing by the β-cell. To assess whether the development of peptides that could convert circulating proinsulin to insulin in the blood would provide therapeutic value, we used a quantitative systems pharmacology (QSP) model of glucose homeostasis. In silico hypothesis testing such as this is an example of how modeling can inform decisions in drug discovery. Methods: In silico hypothesis testing involved (1) the addition and qualification of proinsulin biology into a preexisting QSP model, (2) the creation and validation of virtual patients (VPs) for subpopulations of type 2 diabetics based on phenotypic traits, and (3) the simulation of clinical trials evaluating the therapeutic value of the conversion of circulating proinsulin to insulin in the VPs created. Results: Proinsulin conversion led to a ~0.2% reduction in HbA1c in VPs at varying stages of diabetes, a decrease that does not hold meaningful therapeutic value. The lack of significant impact on HbA1c was likely a result of the surprisingly small effect on plasma insulin levels from proinsulin, which has a significantly slower secretion and clearance rate. Although patients with higher proinsulin/insulin ratios showed the largest reductions, clinically significant ≥ 0.5% reduction in HbA1c required ratios of proinsulin/insulin above the reported physiological range. Conclusions: This effort demonstrates how in silico hypothesis testing using QSP modeling can provide insights on the probability of success of novel interventions with minimal time and resources. These efficiencies are a means of overcoming the pressures on the pharmaceutical industry to do more with less in providing therapies that improve the lives of patients.Keywords
Funding Information
- Merck Sharp & Dohme LLC
This publication has 62 references indexed in Scilit:
- Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and OpportunitiesCPT: Pharmacometrics & Systems Pharmacology, 2019
- Industrialization of Quantitative Systems PharmacologyCPT: Pharmacometrics & Systems Pharmacology, 2019
- Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly StudyDiabetologia, 2002
- Hyperproinsulinaemia in impaired glucose tolerance is associated with a delayed insulin response to glucoseDiabetologia, 1999
- Alteration in brain glucose metabolism induced by hypoglycaemia in man.Diabetologia, 1997
- Fasting proinsulin and 2-h post-load glucose levels predict the conversion to NIDDM in subjects with impaired glucose tolerance: The Hoorn StudyDiabetologia, 1996
- Pathogenesis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overviewDiabetologia, 1992
- Hyperinsulinaemia in obesity is not accompanied by an increase in serum proinsulin/insulin ratio in groups of human subjects with and without glucose intoleranceDiabetologia, 1991
- Serum proinsulin levels at fasting and after oral glucose load in patients with Type 2 (non-insulin-dependent) diabetes mellitusDiabetologia, 1988
- Similar activities of nerve growth factor and its homologue proinsulin in intracellular hydrogen peroxide production and metabolism in adipocytesBiochemical Pharmacology, 1982